vs
Apellis Pharmaceuticals, Inc.（APLS）与Hillman Solutions Corp.（HLMN）财务数据对比。点击上方公司名可切换其他公司
Hillman Solutions Corp.的季度营收约是Apellis Pharmaceuticals, Inc.的1.9倍（$370.1M vs $199.9M），Hillman Solutions Corp.净利率更高（-1.3% vs -29.5%，领先28.2%），Hillman Solutions Corp.同比增速更快（3.0% vs -5.9%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-34.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -1.2%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Hillman Solutions是一家美国企业，核心业务涵盖五金产品制造、分销以及面向消费者的定制加工服务，为市场提供多元化的五金相关解决方案，服务覆盖产业链多个环节。
APLS vs HLMN — 直观对比
营收规模更大
HLMN
是对方的1.9倍
$199.9M
营收增速更快
HLMN
高出8.9%
-5.9%
净利率更高
HLMN
高出28.2%
-29.5%
自由现金流更多
APLS
多$20.1M
$-34.3M
两年增速更快
APLS
近两年复合增速
-1.2%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $370.1M |
| 净利润 | $-59.0M | $-4.7M |
| 毛利率 | — | — |
| 营业利润率 | -25.6% | 1.9% |
| 净利率 | -29.5% | -1.3% |
| 营收同比 | -5.9% | 3.0% |
| 净利润同比 | -62.2% | — |
| 每股收益（稀释后） | $-0.40 | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSHLMN
| Q1 26 | — | $370.1M | ||
| Q4 25 | $199.9M | $365.1M | ||
| Q3 25 | $458.6M | $424.9M | ||
| Q2 25 | $178.5M | $402.8M | ||
| Q1 25 | $166.8M | $359.3M | ||
| Q4 24 | $212.5M | $349.6M | ||
| Q3 24 | $196.8M | $393.3M | ||
| Q2 24 | $199.7M | $379.4M |
净利润APLSHLMN
| Q1 26 | — | $-4.7M | ||
| Q4 25 | $-59.0M | $1.6M | ||
| Q3 25 | $215.7M | $23.2M | ||
| Q2 25 | $-42.2M | $15.8M | ||
| Q1 25 | $-92.2M | $-317.0K | ||
| Q4 24 | $-36.4M | $-1.2M | ||
| Q3 24 | $-57.4M | $7.4M | ||
| Q2 24 | $-37.7M | $12.5M |
营业利润率APLSHLMN
| Q1 26 | — | 1.9% | ||
| Q4 25 | -25.6% | 4.6% | ||
| Q3 25 | 48.7% | 10.8% | ||
| Q2 25 | -18.6% | 9.0% | ||
| Q1 25 | -50.0% | 4.2% | ||
| Q4 24 | -12.3% | 4.0% | ||
| Q3 24 | -24.0% | 6.8% | ||
| Q2 24 | -14.7% | 8.3% |
净利率APLSHLMN
| Q1 26 | — | -1.3% | ||
| Q4 25 | -29.5% | 0.4% | ||
| Q3 25 | 47.0% | 5.5% | ||
| Q2 25 | -23.6% | 3.9% | ||
| Q1 25 | -55.3% | -0.1% | ||
| Q4 24 | -17.1% | -0.3% | ||
| Q3 24 | -29.2% | 1.9% | ||
| Q2 24 | -18.9% | 3.3% |
每股收益（稀释后）APLSHLMN
| Q1 26 | — | $-0.02 | ||
| Q4 25 | $-0.40 | $0.00 | ||
| Q3 25 | $1.67 | $0.12 | ||
| Q2 25 | $-0.33 | $0.08 | ||
| Q1 25 | $-0.74 | $0.00 | ||
| Q4 24 | $-0.30 | $-0.00 | ||
| Q3 24 | $-0.46 | $0.04 | ||
| Q2 24 | $-0.30 | $0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $27.7M |
| 总债务越低越好 | — | $714.1M |
| 股东权益账面价值 | $370.1M | $1.2B |
| 总资产 | $1.1B | $2.4B |
| 负债/权益比越低杠杆越低 | — | 0.59× |
8季度趋势，按日历期对齐
现金及短期投资APLSHLMN
| Q1 26 | — | $27.7M | ||
| Q4 25 | $466.2M | $27.3M | ||
| Q3 25 | $479.2M | $37.7M | ||
| Q2 25 | $370.0M | $34.2M | ||
| Q1 25 | $358.4M | $36.3M | ||
| Q4 24 | $411.3M | $44.5M | ||
| Q3 24 | $396.9M | $59.8M | ||
| Q2 24 | $360.1M | $54.0M |
总债务APLSHLMN
| Q1 26 | — | $714.1M | ||
| Q4 25 | — | $668.3M | ||
| Q3 25 | — | $683.2M | ||
| Q2 25 | — | $683.1M | ||
| Q1 25 | — | $713.5M | ||
| Q4 24 | — | $691.7M | ||
| Q3 24 | — | $730.7M | ||
| Q2 24 | — | $732.1M |
股东权益APLSHLMN
| Q1 26 | — | $1.2B | ||
| Q4 25 | $370.1M | $1.2B | ||
| Q3 25 | $401.2M | $1.2B | ||
| Q2 25 | $156.3M | $1.2B | ||
| Q1 25 | $164.2M | $1.2B | ||
| Q4 24 | $228.5M | $1.2B | ||
| Q3 24 | $237.1M | $1.2B | ||
| Q2 24 | $264.3M | $1.2B |
总资产APLSHLMN
| Q1 26 | — | $2.4B | ||
| Q4 25 | $1.1B | $2.4B | ||
| Q3 25 | $1.1B | $2.4B | ||
| Q2 25 | $821.4M | $2.4B | ||
| Q1 25 | $807.3M | $2.3B | ||
| Q4 24 | $885.1M | $2.3B | ||
| Q3 24 | $901.9M | $2.4B | ||
| Q2 24 | $904.5M | $2.4B |
负债/权益比APLSHLMN
| Q1 26 | — | 0.59× | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | — | 0.57× | ||
| Q1 25 | — | 0.60× | ||
| Q4 24 | — | 0.59× | ||
| Q3 24 | — | 0.62× | ||
| Q2 24 | — | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-34.3M |
| 自由现金流率自由现金流/营收 | -7.1% | -9.3% |
| 资本支出强度资本支出/营收 | 0.1% | 4.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $22.1M |
8季度趋势，按日历期对齐
经营现金流APLSHLMN
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $30.9M | ||
| Q3 25 | $108.5M | $26.2M | ||
| Q2 25 | $4.4M | $48.7M | ||
| Q1 25 | $-53.4M | $-655.0K | ||
| Q4 24 | $19.4M | $43.1M | ||
| Q3 24 | $34.1M | $63.7M | ||
| Q2 24 | $-8.3M | $64.8M |
自由现金流APLSHLMN
| Q1 26 | — | $-34.3M | ||
| Q4 25 | $-14.3M | $16.1M | ||
| Q3 25 | $108.3M | $9.1M | ||
| Q2 25 | $4.4M | $31.2M | ||
| Q1 25 | $-53.4M | $-21.3M | ||
| Q4 24 | $19.3M | $22.1M | ||
| Q3 24 | — | $39.6M | ||
| Q2 24 | $-8.4M | $42.5M |
自由现金流率APLSHLMN
| Q1 26 | — | -9.3% | ||
| Q4 25 | -7.1% | 4.4% | ||
| Q3 25 | 23.6% | 2.1% | ||
| Q2 25 | 2.5% | 7.7% | ||
| Q1 25 | -32.0% | -5.9% | ||
| Q4 24 | 9.1% | 6.3% | ||
| Q3 24 | — | 10.1% | ||
| Q2 24 | -4.2% | 11.2% |
资本支出强度APLSHLMN
| Q1 26 | — | 4.0% | ||
| Q4 25 | 0.1% | 4.0% | ||
| Q3 25 | 0.0% | 4.0% | ||
| Q2 25 | 0.0% | 4.3% | ||
| Q1 25 | 0.0% | 5.7% | ||
| Q4 24 | 0.0% | 6.0% | ||
| Q3 24 | 0.0% | 6.1% | ||
| Q2 24 | 0.0% | 5.9% |
现金转化率APLSHLMN
| Q1 26 | — | — | ||
| Q4 25 | — | 19.33× | ||
| Q3 25 | 0.50× | 1.13× | ||
| Q2 25 | — | 3.08× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 8.57× | ||
| Q2 24 | — | 5.17× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
HLMN
暂无分部数据
